AR026647A1 - Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas - Google Patents
Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicasInfo
- Publication number
- AR026647A1 AR026647A1 ARP000106286A ARP000106286A AR026647A1 AR 026647 A1 AR026647 A1 AR 026647A1 AR P000106286 A ARP000106286 A AR P000106286A AR P000106286 A ARP000106286 A AR P000106286A AR 026647 A1 AR026647 A1 AR 026647A1
- Authority
- AR
- Argentina
- Prior art keywords
- core
- elastomer
- pharmacos
- supply
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/10—Block- or graft-copolymers containing polysiloxane sequences
- C08L83/12—Block- or graft-copolymers containing polysiloxane sequences containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/14—Polysiloxanes containing silicon bound to oxygen-containing groups
- C08G77/18—Polysiloxanes containing silicon bound to oxygen-containing groups to alkoxy or aryloxy groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/42—Block-or graft-polymers containing polysiloxane sequences
- C08G77/44—Block-or graft-polymers containing polysiloxane sequences containing only polysiloxane sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/42—Block-or graft-polymers containing polysiloxane sequences
- C08G77/46—Block-or graft-polymers containing polysiloxane sequences containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/48—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
- C08G77/50—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/70—Siloxanes defined by use of the MDTQ nomenclature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invencion se refiere a un dispositivo para la liberacion controlada durante un período de tiempo prolongado, de un fármaco que tiene propiedadesantiprogestínicas, comprendiendo dicho dispositivo, un nucleo que comprende dicho fármaco, opcionalment e una membrana que encierra dicho nucleo, en el quedicho nucleo y/o membrana están hechos de una composicion elastomero basado en siloxano que comprende al menos un elastomero y posiblemente un polímero noentrecruzado. El dispositivo está caracteriza do porque la composicion de elastomero comprende grupos poli(oxido de alquileno) y porque los grupos poli(oxido dealquileno) están presentes en el elastomero o polímero como injertos terminados con alcoxi de unidades de polisiloxano, o como bloques, estando unidos dichosinjertos o bloques a las unidades de polisiloxano por enlaces silicio-carbono o como mezcla de estas formas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/472,126 US6476079B1 (en) | 1999-12-23 | 1999-12-23 | Devices for the delivery of drugs having antiprogestinic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026647A1 true AR026647A1 (es) | 2003-02-19 |
Family
ID=23874296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000106286A AR026647A1 (es) | 1999-12-23 | 2000-11-29 | Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas |
Country Status (31)
Country | Link |
---|---|
US (1) | US6476079B1 (es) |
EP (1) | EP1239829B1 (es) |
JP (1) | JP4895150B2 (es) |
KR (1) | KR100850548B1 (es) |
CN (1) | CN100346772C (es) |
AR (1) | AR026647A1 (es) |
AT (1) | ATE401859T1 (es) |
AU (1) | AU781555B2 (es) |
BR (1) | BR0016697A (es) |
CA (1) | CA2395226C (es) |
CO (1) | CO5261571A1 (es) |
CZ (1) | CZ301865B6 (es) |
DE (2) | DE60039626D1 (es) |
DK (1) | DK1239829T3 (es) |
EE (1) | EE05123B1 (es) |
ES (1) | ES2310526T3 (es) |
HK (1) | HK1047235B (es) |
HU (1) | HU229438B1 (es) |
IL (2) | IL149663A0 (es) |
MX (1) | MXPA02006174A (es) |
NO (1) | NO332261B1 (es) |
NZ (1) | NZ519876A (es) |
PE (1) | PE20010801A1 (es) |
PL (1) | PL201216B1 (es) |
PT (1) | PT1239829E (es) |
RU (1) | RU2228170C2 (es) |
SK (1) | SK287229B6 (es) |
TW (1) | TWI248367B (es) |
UA (1) | UA70401C2 (es) |
WO (1) | WO2001047490A1 (es) |
ZA (1) | ZA200203620B (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794464B2 (en) | 1998-06-30 | 2004-09-21 | Schering Oy | Membrane or matrix for controlling the permeation rate of drugs |
US6887948B2 (en) * | 1998-06-30 | 2005-05-03 | Schering Oy | Method for preparing a siloxane-based elastomer composition |
AU2002210580A1 (en) * | 2000-10-20 | 2002-04-29 | Leiras Oy | Drug delivery system |
WO2003017971A1 (en) * | 2001-08-31 | 2003-03-06 | Schering Oy | Drug delivery system |
EP1438942A1 (en) * | 2003-01-17 | 2004-07-21 | Schering Oy | An otorhinological drug delivery device |
EP1696822B1 (en) * | 2003-11-13 | 2010-03-17 | PSivida US Inc. | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
CN101437571B (zh) | 2005-10-13 | 2013-01-02 | 斯恩蒂斯有限公司 | 载药包装物 |
US20070149916A1 (en) * | 2005-12-22 | 2007-06-28 | Alza Corporation | Dry matrices as drug reservoirs in electrotransport applications |
EP1862468A1 (de) * | 2006-06-02 | 2007-12-05 | Bayer Schering Pharma Aktiengesellschaft | Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on |
US20080261929A1 (en) * | 2007-04-23 | 2008-10-23 | Jens Hoffmann | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases |
DE102007032468A1 (de) * | 2007-07-10 | 2009-01-15 | Brätter, Christian, Dr. | Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten |
TW200930343A (en) * | 2007-09-21 | 2009-07-16 | Organon Nv | Drug delivery system |
EP2057972A1 (en) * | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine deposit |
TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
DK2349143T4 (en) | 2008-09-17 | 2016-11-28 | Bayer Oy | introducer |
US11992431B2 (en) | 2008-09-17 | 2024-05-28 | Bayer Oy | Inserter |
FI20080523A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
ES2673294T3 (es) * | 2008-11-06 | 2018-06-21 | Novo Nordisk A/S | Dispositivo de administración de fármacos asistido electrónicamente |
US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
US8569421B2 (en) | 2009-04-23 | 2013-10-29 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
US8568374B2 (en) * | 2009-05-04 | 2013-10-29 | Merck Sharp & Dohme B.V. | Intrauterine system |
DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
US20130018027A1 (en) * | 2010-03-22 | 2013-01-17 | Repros Therapeutics Inc. | Compositions and methods for non-toxic delivery of antiprogestins |
US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
US9381193B2 (en) * | 2011-04-01 | 2016-07-05 | Washington University | Contraceptive methods and compositions |
KR20140074281A (ko) * | 2011-07-20 | 2014-06-17 | 패트릭 에프. 카이저 | 약물 전달용 질내 장치 |
TWI590843B (zh) | 2011-12-28 | 2017-07-11 | 信迪思有限公司 | 膜及其製造方法 |
JP6294885B2 (ja) | 2012-08-30 | 2018-03-14 | エーティーアールピー ソリューションズ インコーポレイテッドATRP Solutions,Inc. | 星形高分子、星形高分子組成物および星形高分子の製造方法 |
EP2951220B1 (en) | 2013-02-04 | 2020-11-25 | Pilot Polymer Technologies, Inc. | Salt-tolerant star macromolecules |
EP2953678B1 (en) | 2013-02-06 | 2020-03-25 | Sillender, Mark | Therapeutic substance transfer catheter |
US10188426B2 (en) | 2013-02-06 | 2019-01-29 | Mark SILLENDER | Embryo transfer catheter and method |
WO2014160305A1 (en) * | 2013-03-14 | 2014-10-02 | Albany Molecular Research, Inc. | Ligand-therapeutic agent conjugates and silicon-based linkers |
EP2983671B1 (en) | 2013-04-11 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Progesterone receptor antagonist dosage form |
EP3010560B1 (en) | 2013-06-21 | 2020-01-01 | DePuy Synthes Products, Inc. | Films and methods of manufacture |
US10106818B2 (en) | 2013-08-16 | 2018-10-23 | The J. David Gladstone Institutes | Dual-color HIV reporter system for the detection of latently-infected cells |
DK2982352T3 (en) * | 2014-06-28 | 2018-11-26 | Laboratorios Andromaco S A | CERVICALLY PESSAR CONTAINING PROGESTERON FOR EXTENDED, LONG AND CONTINUOUS RELEASE USED TO PREVENT EARLY BIRTHS |
US10336848B2 (en) | 2014-07-03 | 2019-07-02 | Pilot Polymer Technologies, Inc. | Surfactant-compatible star macromolecules |
WO2016061131A1 (en) | 2014-10-14 | 2016-04-21 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
WO2016138660A1 (en) * | 2015-03-05 | 2016-09-09 | Dow Corning Toray Co., Ltd. | Curable organopolysiloxane composition, a use thereof, and a laminate prepared from the composition |
JP6898856B2 (ja) * | 2015-05-13 | 2021-07-07 | バイエル・オーイュー | 長時間作用型薬物送達装置および避妊におけるその使用 |
CN106546705B (zh) * | 2015-09-21 | 2020-03-17 | 上海复旦张江生物医药股份有限公司 | 一种脂质体药物体外释放的测试方法 |
CN106546706B (zh) * | 2015-09-21 | 2020-03-17 | 上海复旦张江生物医药股份有限公司 | pH梯度主动载药法制备的脂质体药物的体外释放测试方法 |
EP3542786A1 (en) * | 2018-03-21 | 2019-09-25 | ITF Research Pharma, S.L.U. | Progesterone intravaginal devices |
EP4316477A1 (en) | 2018-08-22 | 2024-02-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods for treating cardiac valve disease |
EP3982996A1 (en) | 2019-06-14 | 2022-04-20 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle |
US10918649B2 (en) * | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
TWI803052B (zh) * | 2021-11-12 | 2023-05-21 | 佛教慈濟醫療財團法人 | 經皮遞送裝置及其使用及製造方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832252A (en) * | 1970-09-29 | 1974-08-27 | T Higuchi | Method of making a drug-delivery device |
JPS519003B1 (es) * | 1970-11-07 | 1976-03-23 | ||
US3836560A (en) | 1971-03-08 | 1974-09-17 | Union Carbide Corp | Organosilicone polymers |
US4155991A (en) * | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
US4323488A (en) * | 1979-03-26 | 1982-04-06 | Shin-Etsu Chemical Company Limited | Method for the preparation of silicone-modified polyoxyalkylene polyethers and room temperature-curable compositions therewith |
JPS60148560A (ja) * | 1984-01-17 | 1985-08-05 | 富士システムズ株式会社 | 皮膚用封止材 |
US4600751A (en) * | 1984-12-18 | 1986-07-15 | Dow Corning Corporation | Hydrophilic silicone-organic copolymer elastomers |
CA1257727A (en) * | 1984-12-18 | 1989-07-18 | Chi-Long Lee | Hydrophilic silicone-organic copolymer elastomers |
GB8704755D0 (en) * | 1987-02-28 | 1987-04-01 | Dow Corning Ltd | Pharmaceutical delivery device |
US4951657A (en) * | 1988-04-22 | 1990-08-28 | Dow Corning Corporation | Heat sealable membrane for transdermal drug release |
EP0545002A1 (en) | 1991-11-21 | 1993-06-09 | Kose Corporation | Silicone polymer, paste-like composition and water-in-oil type cosmetic composition comprising the same |
FI95768C (fi) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
US5660848A (en) * | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
JP3201940B2 (ja) * | 1995-09-12 | 2001-08-27 | 信越化学工業株式会社 | 硬化性シリコーンエラストマー組成物及びその製造方法 |
US5811487A (en) * | 1996-12-16 | 1998-09-22 | Dow Corning Corporation | Thickening silicones with elastomeric silicone polyethers |
US5889108A (en) | 1997-06-02 | 1999-03-30 | Dow Corning Corporation | Thickening solvents with elastomeric silicone polyethers |
US6013711A (en) | 1997-06-18 | 2000-01-11 | Ck Witco Corporation | Hydrophilic polysiloxane compositions |
FI103051B1 (fi) | 1997-08-22 | 1999-04-15 | Leiras Oy | Uusia blokkikopolymeerejä ja niiden valmistus |
FI107339B (fi) | 1998-06-30 | 2001-07-13 | Leiras Oy | Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi |
US6063395A (en) * | 1998-11-12 | 2000-05-16 | Leiras Oy | Drug delivery device especially for the delivery of progestins and estrogens |
-
1999
- 1999-12-23 US US09/472,126 patent/US6476079B1/en not_active Expired - Lifetime
-
2000
- 2000-11-08 TW TW089123574A patent/TWI248367B/zh not_active IP Right Cessation
- 2000-11-21 SK SK701-2002A patent/SK287229B6/sk not_active IP Right Cessation
- 2000-11-21 PT PT00979701T patent/PT1239829E/pt unknown
- 2000-11-21 PL PL355994A patent/PL201216B1/pl unknown
- 2000-11-21 DK DK00979701T patent/DK1239829T3/da active
- 2000-11-21 CA CA002395226A patent/CA2395226C/en not_active Expired - Fee Related
- 2000-11-21 BR BR0016697-9A patent/BR0016697A/pt not_active Application Discontinuation
- 2000-11-21 DE DE60039626T patent/DE60039626D1/de not_active Expired - Lifetime
- 2000-11-21 KR KR1020027008236A patent/KR100850548B1/ko not_active IP Right Cessation
- 2000-11-21 EE EEP200200349A patent/EE05123B1/xx not_active IP Right Cessation
- 2000-11-21 CZ CZ20022106A patent/CZ301865B6/cs not_active IP Right Cessation
- 2000-11-21 AT AT00979701T patent/ATE401859T1/de active
- 2000-11-21 IL IL14966300A patent/IL149663A0/xx active IP Right Grant
- 2000-11-21 RU RU2002119587/15A patent/RU2228170C2/ru not_active IP Right Cessation
- 2000-11-21 DE DE1239829T patent/DE1239829T1/de active Pending
- 2000-11-21 UA UA2002076109A patent/UA70401C2/uk unknown
- 2000-11-21 CN CNB008174148A patent/CN100346772C/zh not_active Expired - Fee Related
- 2000-11-21 EP EP00979701A patent/EP1239829B1/en not_active Expired - Lifetime
- 2000-11-21 HU HU0204015A patent/HU229438B1/hu not_active IP Right Cessation
- 2000-11-21 WO PCT/FI2000/001013 patent/WO2001047490A1/en active IP Right Grant
- 2000-11-21 NZ NZ519876A patent/NZ519876A/en not_active IP Right Cessation
- 2000-11-21 ES ES00979701T patent/ES2310526T3/es not_active Expired - Lifetime
- 2000-11-21 MX MXPA02006174A patent/MXPA02006174A/es active IP Right Grant
- 2000-11-21 AU AU17102/01A patent/AU781555B2/en not_active Ceased
- 2000-11-21 JP JP2001548085A patent/JP4895150B2/ja not_active Expired - Fee Related
- 2000-11-29 AR ARP000106286A patent/AR026647A1/es unknown
- 2000-11-30 CO CO00091712A patent/CO5261571A1/es active IP Right Grant
- 2000-12-19 PE PE2000001367A patent/PE20010801A1/es not_active Application Discontinuation
-
2002
- 2002-05-07 ZA ZA200203620A patent/ZA200203620B/en unknown
- 2002-05-14 IL IL149663A patent/IL149663A/en not_active IP Right Cessation
- 2002-06-21 NO NO20023012A patent/NO332261B1/no not_active IP Right Cessation
- 2002-11-29 HK HK02108704.8A patent/HK1047235B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR026647A1 (es) | Dispositivo para el suministro de farmacos que tienen propiedades antiprogestinicas | |
PE20030316A1 (es) | Sistema de suministro de dos o mas agentes terapeuticamente activos | |
DK1299348T3 (da) | Forbindelser og sammensætninger til levering af aktive midler | |
AR018952A1 (es) | Una membrana o matriz para controlar la velocidad de penetracion de farmacos | |
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
CR9351A (es) | Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica | |
ES2157027T3 (es) | Oxazolidinonas sustituidas y su uso como farmacos antibacterianos. | |
ES2140952T3 (es) | Composiciones para el maquillaje de los ojos. | |
DK1343492T3 (da) | Behandling af mucositis | |
BRPI0509053A (pt) | composição farmacêutica anidra e uso de um agente siliconado e de uma composição | |
BRPI0411071A (pt) | sistemas de reticulação para polìmeros de hidroxila | |
UY28067A1 (es) | Formulaciones de deposito de liberacion controlada | |
AR023727A1 (es) | Compuestos empleados en el tratamiento de padecimientos inflamatorios | |
GT199700141A (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas. | |
CR8402A (es) | Indazol-o-glucosidos sustitutos | |
AR030925A1 (es) | Uso de un agente bacteriano y las composiciones cosmeticas, farmaceuticas o veterinarias que contienen dicho agente bacteriano | |
DE60141972D1 (de) | Hydrophile vernetzbare silikone | |
ES2166066T3 (es) | Composiciones antimicrobianas sinergicas que contienen un polimero ioneno y una sal de dodecilamina y sus metodos de utilizacion. | |
ATE544800T1 (de) | Silikon-gruppen enthaltende zusammensetzungen, medizinische geräte und verfahren | |
ES2069686T3 (es) | Reticulacion de prepolimeros de siloxano con funciones (met)acriloxialquenileno. | |
ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
AR009089A1 (es) | Composiciones para el cuidado del color que comprenden un agente fijador de colorante y un polimero y un metodo para proporcionar cuidado de color | |
PE20001365A1 (es) | Dispositivo de suministro de farmacos, especialmente para el suministro de androgenos | |
AR058141A1 (es) | Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas | |
BRPI0400290A (pt) | Agente de liberação de fluorsilicone misto para membros de fusão de silicone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |